302 related articles for article (PubMed ID: 21643487)
1. Intracellular delivery of RNA-based therapeutics using aptamers.
Thiel KW; Giangrande PH
Ther Deliv; 2010 Dec; 1(6):849-61. PubMed ID: 21643487
[TBL] [Abstract][Full Text] [Related]
2. Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP; Giangrande PH
Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
[TBL] [Abstract][Full Text] [Related]
3. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
4. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-siRNA chimeras for HIV.
Takahashi M; Burnett JC; Rossi JJ
Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
[TBL] [Abstract][Full Text] [Related]
6. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
Wang XL; Wang QQ; Song HF
Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
[TBL] [Abstract][Full Text] [Related]
7. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
8. RNA-based therapeutics: current progress and future prospects.
Burnett JC; Rossi JJ
Chem Biol; 2012 Jan; 19(1):60-71. PubMed ID: 22284355
[TBL] [Abstract][Full Text] [Related]
9. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.
Zhou J; Swiderski P; Li H; Zhang J; Neff CP; Akkina R; Rossi JJ
Nucleic Acids Res; 2009 May; 37(9):3094-109. PubMed ID: 19304999
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
11. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
[TBL] [Abstract][Full Text] [Related]
12. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
13. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
Zhou J; Rossi J
J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
[TBL] [Abstract][Full Text] [Related]
14. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of cell-internalizing aptamers.
Zhou J; Rossi JJ
Curr Top Med Chem; 2009; 9(12):1144-57. PubMed ID: 19860714
[TBL] [Abstract][Full Text] [Related]
16. Aptamers as the chaperones (Aptachaperones) of drugs-from siRNAs to DNA nanorobots.
Citartan M; Kaur H; Presela R; Tang TH
Int J Pharm; 2019 Aug; 567():118483. PubMed ID: 31260780
[TBL] [Abstract][Full Text] [Related]
17. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
[TBL] [Abstract][Full Text] [Related]
18. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.
Thiel WH; Thiel KW; Flenker KS; Bair T; Dupuy AJ; McNamara JO; Miller FJ; Giangrande PH
Methods Mol Biol; 2015; 1218():187-99. PubMed ID: 25319652
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
Zhou J; Rossi JJ
BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
